<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03783754</url>
  </required_header>
  <id_info>
    <org_study_id>TRIDENT MRI</org_study_id>
    <nct_id>NCT03783754</nct_id>
  </id_info>
  <brief_title>Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Magnetic Resonance Imaging Sub-study</brief_title>
  <acronym>TRIDENT-MRI</acronym>
  <official_title>Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) MRI Sub-study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The George Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TRIDENT Main Study:&#xD;
&#xD;
      TRIDENT is a multicentre, international, double-blinded, placebo-controlled, parallel-group,&#xD;
      randomised controlled trial of a fixed low-dose combination BP-lowering pill (&quot;Triple Pill&quot;)&#xD;
      strategy on top of standard of care, in patients with a history of acute intracerebral&#xD;
      haemorrhage (ICH) and systolic blood pressure (SBP) levels defined as 'high normal to&#xD;
      borderline high', and on either minimal or no BP-lowering treatment according to current&#xD;
      guidelines.&#xD;
&#xD;
      MRI Sub-Study Centres capable of specific MRI of the brain sequences will be identified. The&#xD;
      patients in the TRIDENT main study who are identified to be eligible for the MRI Sub-Study&#xD;
      will undergo MRI scans at baseline (6 weeks to 6 months post-randomisation) and at 36-month&#xD;
      follow-up time points. All data collected will be analysed centrally at the Brain and Mind&#xD;
      Centre (BMC) in Sydney, Australia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intracerebral haemorrhage (ICH) is the most serious type of stroke, accounting for 10% of&#xD;
      stroke in high-income countries and up to 50% in low-to-middle income countries, especially&#xD;
      in Asia where hypertension is common. ICH in the context of hypertension is often a&#xD;
      manifestation of underlying cerebral small vessel disease (CSVD).&#xD;
&#xD;
      In summary, there is a considerable body of evidence supporting and association of CSVD with&#xD;
      hypertension and poor outcomes, but limited evidence as to whether good BP control can modify&#xD;
      the natural history of this condition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not feasible to continue&#xD;
  </why_stopped>
  <start_date type="Actual">August 9, 2018</start_date>
  <completion_date type="Actual">March 21, 2021</completion_date>
  <primary_completion_date type="Actual">March 21, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Main Study: Multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in T2 FLAIR white matter hyperintensities (WMH) volume</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Whole brain atrophy measured by percentage brain volume change between baseline and 36 months on HIRES-T1.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substructure change - cortical grey matter</measure>
    <time_frame>36 months</time_frame>
    <description>expected range: &gt;400,000 and &lt;800,000mm3 Relevant Sequence: 3D-T1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substructure change - white matter</measure>
    <time_frame>36 months</time_frame>
    <description>expected range: &gt;400,000 and &lt;900,000mm3 Relevant Sequence: 3D-T1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substructure change - cerebrospinal fluid (CSF)</measure>
    <time_frame>36 months</time_frame>
    <description>volume change measured Relevant Sequence: 3D-T1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of cerebral microbleeds (CMBs)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Stroke</condition>
  <condition>Cerebral Small Vessel Diseases</condition>
  <condition>Intracerebral Hemorrhage</condition>
  <condition>Vascular Dementia</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Triple Pill (Active Treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>received via blinded study oral capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan 20 mg + amlodipine 2.5mg + indapamide 1.25mg</intervention_name>
    <description>low-dose combination therapy</description>
    <arm_group_label>Triple Pill (Active Treatment)</arm_group_label>
    <other_name>Triple Pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>matched placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Eligible for, randomised and continuing in TRIDENT Main Study&#xD;
&#xD;
          2. No contraindications to MRI scan of the brain&#xD;
&#xD;
          3. Provide informed consent for the MRI Sub-Study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any MRI contraindications (e.g. metallic implants, claustrophobia, etc.)&#xD;
&#xD;
          2. Less than 6 weeks or greater than 6 months post-randomisation (however, where possible&#xD;
             the baseline MRI Sub-Study scan should be conducted as soon as possible after the&#xD;
             qualifying ICH. e.g. if the qualifying ICH was 4 months prior to randomisation, the&#xD;
             baseline scan should be done as close to 6 weeks post-randomisation as possible)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Anderson, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunshine Coast University Hospital</name>
      <address>
        <city>Birtinya</city>
        <state>Queensland</state>
        <zip>4575</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 6, 2018</study_first_submitted>
  <study_first_submitted_qc>December 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2018</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
    <mesh_term>Cerebral Small Vessel Diseases</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Indapamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

